Short‑term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis&amp;nbsp;B

Sano, Tomoya; Amano, Keisuke; Ide, Tatsuya; Kawaguchi, Toshihiro; Kuwahara, Reiichiro; Arinaga‐Hino, Teruko; Koga, Hironori; Kuromatsu, Ryoko; Torimura, Takuji

doi:10.3892/br.2020.1388

Cited by 4 publications

(12 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The HBV‐DNA negative rates were TDF 76% and ADV 13% in HBeAg positive cases, and TDF 93% and ADV 63% in HBeAg negative cases, and good results were reported in the TDF group regardless of the presence or absence of HBeAg 8 ,. 9 In addition, a phase III study investigating TDF (300 mg/day) versus ETV (0.5 mg/day) in naïve cases reported an average amount of HBV DNA change of −4.86 log copies/ml in the TDF group and −4.85 log copies/ml in the ETV group at 48 weeks 10 . The mean change in HBsAg was −0.208 log IU/ml in the TDF group and −0.051 log IU/ml in the ETV group, indicating a greater reduction in the HBsAg level from baseline in the TDF group.…”

Section: Introductionmentioning

confidence: 99%

Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study

Hagiwara

Nishida

Ueshima

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

Aim: Both entecavir (ETV) and tenofovir alafenamide fumarate (TAF) are widely used to treat chronic hepatitis B (CHB) in Japan. However, it remains unclear whether the efficacy of TAF in decreasing the hepatitis B surface antigen (HBsAg) level, and its safety, are superior to those of ETV. This study aimed to report the long-term effects and safety of 96-week ETV and TAF treatment in patients with CHB.Methods: A prospective comparative observational study was undertaken on the following two groups: patients with CHB who received continuous ETV (n = 32) and patients with CHB who were switched from ETV to TAF upon request (n = 48). The HBsAg, urinary β2-microglobulin (β2MG)/creatinine (Cr), urinary N-acetyl-β-Dglucosaminidase (NAG)/Cr, and serum alanine aminotransferase (ALT) levels, estimated glomerular filtration rate (eGFR), and bone mineral density (lumbar spine and femur) at 96 weeks were compared. Results:The two groups did not significantly differ with respect to mean age, male / female patient ratio, or rate of hepatitis B e antigen-positive status. The mean changes in serum HBsAg level and eGFR at 96 weeks were not significantly different between the two groups. The β2MG/Cr and NAG/Cr levels at 96 weeks were similar between the two groups. Additionally, the bone mineral density of the lumbar spine and femur as well as the serum ALT did not significantly differ. Conclusions:When compared with patients who received continuous ETV, those who were introduced to TAF after ETV showed similar effects in terms of the decrease in HBsAg level and safety.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study

Hagiwara

Nishida

Ueshima

et al. 2021

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…Current data suggest that switching these patients to TAF may help avoid poor long‐term outcomes. Improvements or maintenance in virological outcomes upon switching from other NAs or combinations of NAs to TAF have been reported 59,60,63‐65,67‐71 . TDF and/or ETV were the most commonly reported prior NAs, but several studies included a high proportion of patients treated with other prior NAs 59,60,63‐65,69 .…”

Section: Discussion and Clinical Implicationsmentioning

confidence: 99%

“…Bone safety was not reported in most studies of TAF switching from ETV or other NAs. With respect to renal safety, switching from ETV or other NAs to TAF had no clear benefit 49,54‐59,61,63‐72 …”

Section: Discussion and Clinical Implicationsmentioning

confidence: 99%

Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data

Lim

Seto

Kurosaki

et al. 2022

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB). However, resistance to ETV has been reported, especially with prior exposure to other NAs, and long‐term TDF treatment has been associated with decline in renal function and loss of bone mineral density in some patients. Consequently, TAF may be preferable to ETV, TDF or other NAs in specific circumstances such as in patients with risk of bone or renal complications, elderly patients or those with previous NA experience. Aim To provide a summary of the available efficacy and safety data following switch to TAF from other NAs in patients with CHB in clinical studies and real‐world settings. Methods Literature searches were performed on PubMed and abstracts from three major international liver congresses between 2019 and 2021. Studies that included efficacy and/or safety data for patients with CHB switching from any NA to TAF were selected. Results Thirty‐six papers and abstracts were included in this narrative review. Switching from TDF to TAF maintained or improved virological and biochemical responses with improved bone and renal safety. Switching from ETV or other NAs to TAF maintained or improved virological and biochemical responses and varying results for bone and renal safety. Conclusions Switching to TAF appears to maintain or improve virological, biochemical and bone‐ and renal‐related safety outcomes. These data support the concept of switching to TAF in some patients with CHB based on their individual circumstances.

show abstract

“…However, the majority of the enrolled subjects showed normal renal function at the baseline and, therefore, enrolled subjects were not suitable for the evaluation of the effect of TAF on NAs-related renal tubular dysfunction [ 48 ]. On the other hand, the other five studies have demonstrated that switching from ADV/TDF to TAF improved renal function [ 49 , 50 , 51 , 52 , 53 ]. Three prospective single-arm open-label studies demonstrated that beneficial effects on renal functions and BMD were observed in the patients switched to TAF than in patients treated with TDF [ 48 , 51 , 52 ].…”

Section: Effects Of Switching To Taf On Nas-related Renal Tubular mentioning

confidence: 99%

“…In addition, Ogawa E. et al reported that switching to TAF improves renal dysfunction associated with various NA combinations (LAM/ETV and ADV/TDF) [ 50 ]. We also reported that switching from ADV/TDF to TAF improves U-BMG/Cr ratio and bone specific alkaline phosphatase even in CHB patients with long-term treatment of ADV (9.8 ± 3.0 years) [ 53 ]. Therefore, switching to TAF is an important therapeutic strategy for CHB patients with NAs-related renal tubular dysfunction.…”

Section: Effects Of Switching To Taf On Nas-related Renal Tubular mentioning

confidence: 99%

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B

Sano

Kawaguchi

Ide

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

Nucles(t)ide analogs (NAs) are effective for chronic hepatitis B (CHB). NAs suppress hepatic decompensation and hepatocarcinogenesis, leading to a dramatic improvement of the natural course of patients with CHB. However, renal dysfunction is becoming an important issue for the management of CHB. Renal dysfunction develops in patients with the long-term treatment of NAs including adefovir dipivoxil and tenofovir disoproxil fumarate. Recently, several studies have reported that the newly approved tenofovir alafenamide (TAF) has a safe profile for the kidney due to greater plasma stability. In this mini-review, we discuss the effectiveness of switching to TAF for NAs-related renal tubular dysfunction in patients with CHB.

show abstract

Short‑term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B

Cited by 4 publications

References 46 publications

Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study

Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long‐term effects from a prospective study

Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B

Contact Info

Product

Resources

About